Inhibrx Biosciences Ratios (2023-2025) | INBX

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -156,823.33%-43,518.49%-5,628.76%968.14%1,858,013.00%-47,865.00%1,610.67%-2,204.00%
EBIT Margin -137,796.67%-38,510.08%-5,403.24%908.06%-160,898.00%-49,928.00%1,595.43%-2,106.85%
EBITDA Margin -137,796.67%-38,510.08%-5,403.24%908.06%-160,898.00%-49,928.00%1,595.43%-2,106.85%
Operating Margin -137,796.67%-38,510.08%-5,403.24%908.06%-160,898.00%-49,928.00%1,595.43%-2,106.85%
Net Margin -156,840.00%-43,520.17%-5,628.52%968.14%1,858,011.00%-47,865.00%1,610.67%-2,204.15%
FCF Margin -46,062.18%-3,688.07%789.29%-58,573.00%-43,736.00%1,335.66%-2,304.08%
Efficiency
Assets Average 240.49M201.66M211.70M227.38M194.79M
Equity Average 198.92M156.03M114.01M81.50M52.69M
Invested Capital 43.50M219.37M178.47M133.58M193.10M167.84M136.75M
Asset Utilization Ratio -0.03-0.04-0.01-0.01-0.01
Leverage & Solvency
Interest Coverage Ratio -5.23-5.62-10.74-9.08-30.01-15.95-8.72-10.63
Debt to Equity 4.761.041.452.71
Debt Ratio 0.670.410.470.56
Equity Ratio 0.140.850.800.740.390.320.21
Times Interest Earned -5.23-5.62-10.74-9.08-30.01-15.95-8.72-10.63
Valuation
Enterprise Value -277.92M-226.90M-196.33M-152.60M-216.52M-186.60M-153.10M
Return Ratios
Return on Sales -1,568.40%-435.20%-56.29%9.68%18,580.11%-256.95%-478.65%16.11%-22.04%120.31%
Return on Capital Employed -1.88%-2.06%-1.79%-0.89%-0.97%
Return on Invested Capital -1.86%-2.12%-1.84%-0.93%-1.01%
Return on Assets 6.83%8.37%8.14%-0.72%-0.80%
Return on Equity 8.26%10.82%15.11%-2.01%-2.94%